Drug interaction ontology (DIO) for inferences of possible drug-drug interactions

Studies in Health Technology and Informatics

Volumn 107, Issue , 2004, Pages 454-458

  Yoshikawa, Sumi ^a   Satou, Kenji ^b   Konagaya, Akihiko ^a  

^a RIKEN   (Japan)

^b JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

computational biology; Drug interactions; knowledge representation; molecular functions; pharmacology

Indexed keywords

BIOMOLECULES; CHEMICAL DETECTION; COMPUTER SOFTWARE REUSABILITY; KNOWLEDGE BASED SYSTEMS; KNOWLEDGE REPRESENTATION; ONTOLOGY; QUERY PROCESSING; SEMANTICS; DRUG INTERACTIONS;

BIOLOGICAL INTERACTIONS; BIOMOLECULE INTERACTIONS; COMPUTATIONAL BIOLOGY; FORMAL REPRESENTATIONS; MOLECULAR FUNCTION; MOLECULAR PHARMACOLOGY; PHARMACOLOGY; SYMBOLIC REPRESENTATION; DRUG-DRUG INTERACTIONS; KNOWLEDGE COMPONENTS; KNOWLEDGE-REPRESENTATION; ONTOLOGY'S; REUSABLE KNOWLEDGE;

DRUG INTERACTIONS; KNOWLEDGE REPRESENTATION;

EID: 70349647565     PISSN: 09269630     EISSN: 18798365     Source Type: Book Series    
DOI: 10.3233/978-1-60750-949-3-454     Document Type: Article

References (13)

1. Karp PD. An ontology for biological function based on molecular interactions. Bioinformatics 2000: 16:269-85.
2. Bader GD, Hogue CWV. BIND-a data specification for storing and describing biomolecular interactions, molecular complexes and pathways. Bioinformatics 2000: 16: 465-77.
3. Schomburg I, Chang A, Schomburg D. Brenda, enzyme data and metabolic information. Nucleic Acids Research 2002: 30: 47-9.
4. Xenarios I, Salwinski L, Duan XJ, Higney P, Kim S, Eisen-berg D. DIP: The Database of Interacting Proteins. A research tool for studying cellular networks of protein interactions. Nucleic Acids Research:2002: 30: 303-5.
5. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG database at GenomeNet. Nucleic Acids Research 2002:30: 42-6
6. Helden J, Nairn A, Mancuso R, Eldridge M, Wernisch L,. Gilbert D,.Wodak S, Representing and analyzing molecular and cellular function in the computer. Biol Chem 2000: 381:921-35.
7. Okuda H, Ogura K, Kato A, Takubo H and Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998: 287: 791-99.
8. Nishiyama T, Ogura K, Okuda H, Suda K, Kato A, Watabe T. Mechanism-Based Inactivation of Human Dihydropyrim-idine Dehydrogenase by (E)-5-(2-Bromovinyl) uracil in the Presenceof NADPH. Molecular Pharmacology 2000: 57: 899-905.
9. Desgranges C, Razaka G, Clercq ED, Herdewijn P, Balzarini J, Drouillet F, Bricaud H. Effect of (E)-5-(2-bro-movinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986: 46: 1094-101.
10. Nishimoto T, Yokoyama N, Sakamoto H, Ohata K, Kohno S, Murai K and Tatsumi H. Studies on the metabolic fate of Brovavir (YN-72) II: Metabolism in rats. Iyakuhin Ken-kyu.1990: 21: 378-89.
11. Ogiwara T, Miue H, Nakamaru M, Ohtsuka T and Kuma-hara Y. Phase I clinical study of YN-72 (BV-araU, Brovavir). Jpn Pharmacol Ther 1990: 18: 507-23.
12. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorou-racil-induced toxicity. J.Clin.Investig.1988: 81: 47-51, 1988.
13. Schuffenhauer A, Zimmermann J, Stoop R, van der Vyver J, Lecchini S, Jacoby E. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci 2002: 42: 947-55.